Registry-listed formulations

pegzilarginase · mesh:C000732077

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 4 studies. This list may not include all unresolved or historical entries.

  • PegzilarginaseRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • AEB1102Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • PegzilarginaseRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Loargys 5 mg/ml solution for injection/infusionRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: SOLUTION FOR INJECTION/INFUSION

    View study and source

Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
2(40%)

Phase Distribution

Phase 3
3
60%
Phase 2
1
20%
Phase 1/2
1
20%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1/2Combined phases
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 1/21 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1_2

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

NCT03371979
completedphase_2

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency

NCT03378531
completedphase_3

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

NCT03921541
completedphase_3

Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

NCT06582524
terminatedphase_3

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

NCT05676853

Clinical Trials (5)

Showing 5 of 5 trials
NCT03371979Phase 1/2

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Terminated
NCT03378531Phase 2

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency

Completed
NCT03921541Phase 3

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Completed
NCT06582524Phase 3

Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

Completed
NCT05676853Phase 3

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Terminated

All 5 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Enzyme
Total Trials
5

External References

ChEMBL
CHEMBL4297803

Names & Codes

ATC Classification

A16AB24

Research Codes

AEB-1102